RE:I liked this point as well...vestor111 wrote
I liked seeing this point but I believe under the new FDA guidelines, TLT would be rated 100% CR due to the new guidelines allowing exclusion of patients found to be outside the scope of the trial. Recall it was determined that P4 had cancer that spread beyond the bladder and therefore beyond the scope of the trial.
The recent news from both patient five and six cancer-free status at 540 days from the Phase Ib study, which represents a 67% Complete Response ("CR") rate, supports the strong contention that the TLD-1433 Anti-Cancer Technology ("ACT") platform has the potential to be a viable treatment solution for CIS NMIBC BCG-Unresponsive patients, if the Company is able to duplicate the efficacy results observed in the Phase Ib clinical study."
________________________________________________________________________________
That would be great with a corrected rating of 100% and with PH2 underway every patient scoring 100% will solidify the breakthru and ease of treatment Theralase has accomplished.